Analyzing Novavax (NVAX) & Its Rivals
Novavax (NASDAQ: NVAX) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Novavax to similar companies based on the strength of its dividends, analyst recommendations, institutional ownership, earnings, valuation, profitability and risk.
This is a summary of current recommendations and price targets for Novavax and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Novavax presently has a consensus price target of $3.35, indicating a potential upside of 193.86%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 5.17%. Given Novavax’s higher possible upside, research analysts clearly believe Novavax is more favorable than its peers.
Institutional & Insider Ownership
45.2% of Novavax shares are held by institutional investors. Comparatively, 47.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 4.0% of Novavax shares are held by company insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Novavax and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Novavax has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Comparatively, Novavax’s peers have a beta of 1.67, indicating that their average stock price is 67% more volatile than the S&P 500.
Earnings and Valuation
This table compares Novavax and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Novavax||$21.04 million||-$186.64 million||-1.48|
|Novavax Competitors||$207.80 million||-$2.19 million||-0.33|
Novavax’s peers have higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Novavax peers beat Novavax on 9 of the 12 factors compared.
Novavax Company Profile
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company’s product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company’s lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.